Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067634 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
A Phase 3 study of Partial Epilepsy, sponsored by SK Life Science.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT05067634 is a Phase 3 study of Partial Epilepsy that is actively recruiting participants, run by SK Life Science. The registered enrollment target is 140 participants, below the 501-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05067634, a Phase 3 study of Partial Epilepsy, is actively recruiting participants, sponsored by SK Life Science.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Conditions Studied
Interventions
- DRUG Xcopri
Study Locations (20)
Georgia
- Augusta University Medical Center - Augusta
- Clinical Integrative Research Center of Atlanta - Sandy Springs
- Meridian Clinical Research - Savannah Neurology Specialists - Savannah
Ohio
- Akron Children's Hospital NeuroDevelopmental Science Center/Pediatric Neurology - Akron
- Cincinnati Children's Hospital - Cincinnati
- Cleveland Clinic Main Campus - Cleveland
California
- Lucile Packard Children's Hospital Stanford - Palo Alto
- University of California Davis Health - Sacramento
New Jersey
- Northeast Regional Epilepsy Group - Hackensack
- Northeast Regional Epilepsy Group - Morristown - Morristown
Arizona
- Phoenix Children's Hospital - Phoenix
Connecticut
- Connecticut Children's Medical Center - Hartford
Kentucky
- Kentucky Clinic - Lexington
Maryland
- Mid-Atlantic Epilepsy and Sleep Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067634
The ClinicalTrials.gov registry entry for NCT05067634 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (72% lower). The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Xcopri is the first listed.
NCT05067634 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Georgia, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05067634 about?
NCT05067634 is a clinical study titled "Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures". Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
What is the current status of trial NCT05067634?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2022-01-14. Estimated completion is 2026-07.
What conditions does trial NCT05067634 study?
This clinical trial studies the following conditions: Partial Epilepsy.
What interventions are being tested in trial NCT05067634?
The interventions under investigation include: Xcopri (DRUG).
Who is sponsoring clinical trial NCT05067634?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067634 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
COMPLETED · Phase 3
-
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
COMPLETED · Phase 3
-
Surgery as a Treatment for Medically Intractable Epilepsy
RECRUITING
-
Investigating Epilepsy: Screening and Evaluation
RECRUITING
-
Metabolic Abnormalities in Children With Epilepsy
COMPLETED
-
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.